Our results revealed a greater abundance of B cells in HER2-positive DCIS than in HER2-positive invasive tumors and HER2-negative DCIS and invasive tumors, validating previous findings [23, 24]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.